Summer Sale

Up to 30% off — ends 7 Aug

ONLY00h00m00s

Get 30% Off

Up to 30% off — ends 7 Aug

ONLY00h00m00s

Tobias Puengel

Charité - Universitätsmedizin Berlin

Germany

This profile is automatically generated from trusted academic sources.

Google Scholar

ORCID

How do I reach out?

Meet Kite AI

Contact this professor

ORCID

Google Scholar

Research Interests

Clinical Nutrition

30%

Cell Biology

30%

Fatty Liver

70%

Liver Fibrosis

40%

Cholesterol Metabolism

40%

Immunometabolism

30%

Pulmonary Fibrosis

20%

Ask ApplyKite AI

Start chatting

How can you help me contact this professor?

What are this professor's research interests?

How should I write an email to this professor?

Articles16

Soluble Urokinase Plasminogen Activator Receptor Predicts Survival and Hepatic Decompensation in Advanced Hepatocellular Carcinoma.

Article Link

Year:

2025

Pharmacotherapeutic options for metabolic dysfunction-associated steatotic liver disease: where are we today?

Article Link

Year:

2024

Acquisition of epithelial plasticity in human chronic liver disease

Article Link

Year:

2024

Cell type‐specific actions of thyroid hormones in nonalcoholic steatohepatitis and liver fibrosis

Article Link

Year:

2024

Dissecting Acute Drug-Induced Hepatotoxicity and Therapeutic Responses of Steatotic Liver Disease Using Primary Mouse Liver and Blood Cells in a Liver-On-A-Chip Model.

Article Link

Year:

2024

Extracellular Vesicles May Predict Response to Atezolizumab Plus Bevacizumab in Patients with Advanced Hepatocellular Carcinoma

Article Link

Year:

2024

Serum CXCL5 Detects Early Hepatocellular Carcinoma and Indicates Tumor Progression

Article Link

Year:

2023

An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH

Article Link

Year:

2023

Efruxifermin, an investigational treatment for fibrotic or cirrhotic nonalcoholic steatohepatitis (NASH)

Article Link

Year:

2023

Combined Therapy with a CCR2/CCR5 Antagonist and FGF21 Analogue Synergizes in Ameliorating Steatohepatitis and Fibrosis

Article Link

Year:

2022

Soluble Urokinase Plasminogen Activator Receptor Levels Are Associated with Severity of Fibrosis in Patients with Primary Sclerosing Cholangitis

Article Link

Year:

2022

Nuclear Receptors Linking Metabolism, Inflammation, and Fibrosis in Nonalcoholic Fatty Liver Disease

Article Link

Year:

2022

Cenicriviroc for the treatment of COVID-19: first interim results of a randomised, placebo-controlled, investigator-initiated, double-blind phase II trial.

Article Link

Year:

2022

Low Serum Levels of Soluble Receptor Activator of Nuclear Factor κ B Ligand (sRANKL) Are Associated with Metabolic Dysregulation and Predict Long-Term Mortality in Critically Ill Patients.

Article Link

Year:

2021

Monocyte dysregulation: consequences for hepatic infections

Article Link

Year:

2021

Editorial: prevalence, progression rates and mortality predictors of non‐alcoholic fatty liver disease reflected by German statutory health insurance data

Article Link

Year:

2020

Collaborators14

Julie Sellau

Bernhard-Nocht-Institut für Tropenmedizin

GERMANY

Scott Friedman

Dean for Therapeutic Discovery

Icahn School of Medicine at Mount Sinai

UNITED STATES

Jonathan Frederik Brozat

Charité - Universitätsmedizin Berlin

GERMANY

Moritz Peiseler

Charité - Universitätsmedizin Berlin

GERMANY

Albrecht Eisert

Assistent Professor

University Hospital

GERMANY

Sander Lefere

Ghent University

BELGIUM

Ludovic Vallier

Professor

Berlin Institute of Health at Charité - Universitätsmedizin Berlin

GERMANY

Florian Kurth

Bernhard-Nocht-Institut für Tropenmedizin

GERMANY

Bruno Lapauw

Ghent University Hospital

BELGIUM

Raphael Mohr

Charité - Universitätsmedizin Berlin

GERMANY

Lindsey Devisscher

Professor ZAP

BELGIUM

Philipp Hohlstein

RWTH Aachen University

GERMANY

Frank Tacke

GERMANY

Alexander Wree

Charité - Universitätsmedizin Berlin

GERMANY

How do I reach out?

Meet Kite AI